Identification of aryl sulfonamides as novel and potent inhibitors of Na

Dose-Response Relationship, Drug Humans Molecular Structure NAV1.5 Voltage-Gated Sodium Channel / metabolism Structure-Activity Relationship Sulfonamides / chemical synthesis
Aryl sulfonamide Cardiac arrhythmia LQT-3 Na(V)1.5

Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 08 2021
Historique:
received: 07 04 2021
revised: 11 05 2021
accepted: 19 05 2021
pubmed: 28 5 2021
medline: 6 1 2022
entrez: 27 5 2021
Statut: ppublish

Résumé

We describe the synthesis and biological evaluation of a series of novel aryl sulfonamides that exhibit potent inhibition of Na

Identifiants

DOI: 10.1016/j.bmcl.2021.128133 PMID: 34044121
pubmed: 34044121
pii: S0960-894X(21)00359-0
doi: 10.1016/j.bmcl.2021.128133
pii:
doi:

Substances chimiques

NAV1.5 Voltage-Gated Sodium Channel 0
Sulfonamides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

128133

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Shaoyi Sun (S)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada. Electronic address: ssun@xenon-pharma.com.

Qi Jia (Q)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Alla Y Zenova (AY)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Sophia Lin (S)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Angela Hussainkhel (A)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Janette Mezeyova (J)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Elaine Chang (E)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Samuel J Goodchild (SJ)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Zhiwei Xie (Z)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Andrea Lindgren (A)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Gina de Boer (G)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Rainbow Kwan (R)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Kuldip Khakh (K)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Luis Sojo (L)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Paul Bichler (P)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

J P Johnson (JP)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

James R Empfield (JR)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Charles J Cohen (CJ)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Christoph M Dehnhardt (CM)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Richard Dean (R)

Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › Identification of aryl sulfonamides as novel...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Identification of aryl sulfonamides as novel...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Identification of aryl sulfonamides as novel...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Canaux sodiques voltage-dépendants › Canal sodique voltage-dépendant NAV1.5 › Identification of aryl sulfonamides as novel...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Identification of aryl sulfonamides as novel...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Identification of aryl sulfonamides as novel...